Moreover, TIGIT inhibition has been shown to enhance natural killer (NK) cell function in RA patients, although these data have not yet been translated into interventional trials, thus belonging to the category of early-phase human RA data [109]. This evidence concerns the gene TIGIT and rheumatoid arthritis.